Wallace Advisory Group LLC Buys 503 Shares of Eli Lilly and Company $LLY

Key Points

• Wallace Advisory Group LLC increased its holdings in Eli Lilly and Company by 45.7% during the second quarter, acquiring 503 additional shares to reach a total of 1,604 shares valued at approximately $1.3 million.
• Multiple hedge funds have significantly expanded their stakes in Eli Lilly, with PNC Financial Services Group raising its holdings by 97.5% to 101,305,650 shares, and Cohen Investment Advisors increasing theirs by an astonishing 7,975.5%.
• Analyst ratings for Eli Lilly include a recent upgrade from BMO Capital Markets, raising its target price from $840.00 to $930.00, leading to a current consensus rating of "Moderate Buy" and a consensus price target of $938.61.

Wallace Advisory Group LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 45.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,604 shares of the company's stock after purchasing an additional 503 shares during the quarter. Eli Lilly and Company makes up about 0.9% of Wallace Advisory Group LLC's holdings, making the stock its 27th biggest position. Wallace Advisory Group LLC's holdings in Eli Lilly and Company were worth $1,325,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. grew its holdings in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC purchased a new position in shares of Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Cohen Investment Advisors LLC increased its stake in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after acquiring an additional 773,947 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an "outperform" rating in a report on Monday. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, The Goldman Sachs Group upped their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $938.61.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $808.88 on Tuesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $765.57 billion, a P/E ratio of 52.87, a P/E/G ratio of 1.15 and a beta of 0.47. The stock's fifty day moving average is $756.56 and its 200 day moving average is $766.20.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.